

Transformation of Amino Acids into Nonracemic 1-(Heteroaryl)ethanamines by the Enamino Ketone Methodology

by Samo Pirc, David Bevk, Amalija Golobič, Branko Stanovnik*, and Jurij Svete*

Faculty of Chemistry and Chemical Technology, University of Ljubljana, P. O. Box 537,
SI 1001 Ljubljana, Slovenia

(phone: +38661 1760254; fax: +38661 1258220; e-mail: jurij.svete@fkkt.uni-lj.si,
branko.stanovnik@fkkt.uni-lj.si)

N-Protected L-phenylalanines **1a,b** were transformed, *via* the corresponding *Weinreb* amides **2** and ethynyl ketones **3**, into chiral enamino ketones **4** (Scheme 1). Similarly, L-threonine **6** was transformed in four steps into the enamino ketone **10**. Cyclocondensations of **4** and **10** with pyrazolamines **11**, benzenecarboximidamide (**12**), and hydrazine derivatives **18** afforded *N*-protected 1-heteroaryl-2-phenylethanamines **15a–e**, **16**, **17**, and **21a–k** and 1-heteroaryl-1-aminopropan-2-ols **23a,b** in good yields (Schemes 2 and 3). Finally, deprotection by catalytic hydrogenation furnished free amines **22a–g** and **24a,b** (Scheme 3).

Introduction. – Nonracemic amines and α -amino alcohols represent important groups of organic compounds, which found a widespread use in various applications, such as reagents in organic synthesis and resolving agents, chiral auxiliaries and ligands in asymmetric synthesis (for an illustration, see [1]). A typical example of a synthetic application of enantiomerically pure α -amino alcohols is their use as chiral catalysts in asymmetric reactions, such as additions of dialkylzinc to aldehydes (for an illustration, see [2]) and asymmetric reductions of ketones with borane complexes (for an illustration, see [3]). Such examples are (+)-methylbenzylamine, amphetamine, (+)-ephedrine, (1*S*,2*R*)-2-amino-1,2-diphenylethanol, and (*S*)- α,α -diphenylprolinol (Fig. 1).




Fig. 1. Some examples of important 2-phenylethanamines and α -amino alcohols

Recently, a series of alkyl 2-substituted 3-(dimethylamino)prop-2-enoates and related enamino ketones have been prepared as versatile reagents for the preparation of various dihydroalanine derivatives, heterocyclic systems, and natural-product ana-

logs. In extension, chiral cyclic enamino lactams and lactones, derived from α -amino acids and (+)-camphor have been employed in the synthesis of functionalized heterocycles, such as (heteroaryl)alanines, (heteroaryl)alaninols, (heteroaryl)propanediols, 3-(heteroaryl)camphors, and heterocyclic compounds with an α -amino acid or dipeptide structural element incorporated into the ring system (for recent reviews, see [4]; for recent publications, see [5]). Recently, alkyl 2-substituted 3-(dimethylamino)prop-2-enoates and related enamino ketones have been employed in a combinatorial synthesis of heterocycles and *N*-acyldihydroalanine esters [6] and in the synthesis of natural-product analogs, such as aplysinopsins [7] and meridianins [4a] [8].


The 3-(dimethylamino)prop-2-enoates and their chiral analogs are usually prepared by treatment of a suitably functionalized methylene compound with formamide acetal, e.g., with *N,N*-dimethylformamide dimethyl acetal or with *tert*-butoxy-*N,N,N',N'*-tetramethylmethanediamine (*Bredereck's* reagent) [4]. On the other hand, *Giacomelli* and co-workers reported the preparation of acyclic chiral enamino ketones from commercially available α -amino acids by treatment of a suitably protected *Weinreb* amide of an α -amino acid with (trimethylsilyl)magnesium bromide to give the corresponding silyl ynone, followed by reaction with Et_2NH to afford the enamino ketone. These enamino ketones were then used in reactions with various α -hydrazino acids and phenylhydrazine to afford pyrazole-containing peptidomimetics [9] and α -pyrazoylglycines [10].

Within this context and in continuation of our research in the field of chiral enamino ketones, we now report the preparation of chiral acyclic enamino ketones **4a,b** and **10** from α -amino acids and their utilization in a two-step synthesis of 1-(heteroaryl)-2-phenylethanamines **22** and 1-(heteroaryl)-1-aminopropan-2-ols **24**.

Results and Discussion. – First, *Weinreb* amides **2a,b** were prepared from *N*-protected L-phenylalanines **1a,b** according to a known procedure [11]. Treatment of **2a** and **2b** with ethynylmagnesium bromide followed by quenching excess *Grignard* reagent with aqueous NaHSO_4 solution afforded the ynones **3a** and **3b**. Upon reaction of **3a,b** with Et_2NH in CH_2Cl_2 at 0° , the desired enamino ketones **4a** and **4b** were obtained in 86% and 92% yield, respectively. However, *tert*-butyl {(1*S*,3*E*)-1-benzyl-4-[methoxy(methyl)amino]-2-oxobut-3-enyl}carbamate (**5**) was isolated instead of the expected ynone **3b**, when aqueous ammonium chloride was used for quenching of the reaction mixture obtained upon treatment of **2b** with ethynylmagnesium bromide. This could be explained by initial formation of **3b** as the intermediate and *N,O*-dimethylhydroxylamine as the by-product, which undergoes addition to the polarized triple bond of **3b** to give the enamino ketone **5**. Similarly, *N*-[(benzyloxy)carbonyl]-L-threonine (**6**) was transformed in three steps into the *Weinreb* amide **9** according to the literature procedure [12]. Reaction of **9** with ethynylmagnesium bromide followed by quenching with aqueous NH_4Cl afforded benzyl (4*S*,5*R*)-4-[(2*E*)-3-[methoxy(methyl)amino]prop-2-enoyl]-2,2,5-trimethyloxazolidine-3-carboxylate (**10**) in 73% yield (*Scheme 1*, *Table*).

Cyclocondensations of enamino ketones **4a,b** and **10** with 1*H*-pyrazole-3-amine (**11a**), 5-methyl-1*H*-pyrazole-3-amine (**11b**), and 3-amino-1*H*-pyrazole-4-carbonitrile (**11c**) in EtOH at 20 – 80° in the presence of an equimolar amount of aqueous HCl solution afforded 1-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-substituted [(1*S*)-2-phenylethyl]carbamates **15a–e** and [(1*R*,2*R*)-2-hydroxypropyl]carbamate **16** in 20–77% yields.

Scheme 1



a) ClCOOBu , *N*-methylmorpholine, AcOEt , 0° , then MeNHOMe , $0^\circ \rightarrow \text{r.t.}$ b) $\text{HC}\equiv\text{CMgBr}$, THF, $-78^\circ \rightarrow \text{r.t.}$, then aq. NaHSO_4 soln. c) Et_2NH , CH_2Cl_2 , $0^\circ \rightarrow \text{r.t.}$ d) $\text{HC}\equiv\text{CMgBr}$, THF, $-78^\circ \rightarrow \text{r.t.}$, then aq. NH_4Cl soln. e) $\text{Me}_2\text{C}(\text{OMe})_2$, $\text{BF}_3 \cdot \text{Et}_2\text{O}$, r.t. f) MeI , K_2CO_3 , acetone, $0^\circ \rightarrow \text{r.t.}$ g) $i\text{-PrMgBr}$, MeNHOMe , THF, $-78^\circ \rightarrow -20^\circ$, then aq. NH_4Cl soln.

Under these reaction conditions, **4b** did not react with benzenecarboximidamide hydrochloride (**12**). However, in the presence of K_2CO_3 , cyclocondensation took place to afford *tert*-butyl [(1*S*)-2-phenyl-1-(2-phenylpyrimidin-4-yl)ethyl]carbamate (**17**) in 27% yield. According to the general reactivity of *N,N*-dimethyl(enamino) ketones [4], these cyclocondensations can be explained by initial substitution of the diethyl-amino group followed by condensation with the keto group (Scheme 2, Table).

Next, cyclocondensations of enamino ketones **4a,b** and **10** with the hydrazine derivatives hydrazine hydrochloride (**18a**·HCl), phenylhydrazine hydrochloride (**18b**·HCl), (4-nitrophenyl)hydrazine (**18c**), (4-methoxyphenyl)hydrazine (**18d**), (2-bromophenyl)hydrazine hydrochloride (**18e**·HCl), 2-hydrazinopyridine (**18f**), 2-hydrazinopyrimidine (**18g**), 6-chloro-3-hydrazinopyridazine (**18h**), and 3-hydrazino-6-phenylpyridazine (**18i**) were studied. When **4a,b** were treated with **18a–i** in EtOH in the presence of 1 equiv. of aqueous HCl solution¹⁾, *N*-protected (1*S*)-2-phenyl-1-pyrazolyl-ethanamines **21a–k** were obtained in 54–98% yields. Also in this case, the reaction can be explained by substitution of the diethylamino group to give the enehydrazino ketone **19**, which cyclizes into the dihydropyrazole **20**, from which H_2O is eliminated to give the 2-phenyl-1-pyrazolylethanamine **21** [4][13]. Compounds **21a,b**, obtained from **4a,b** and $\text{N}_2\text{H}_4 \cdot \text{HCl}$ (**18a**), exist in solution as mixtures of 1*H*-pyrazol-5-yl and -3-yl isomers **21a,b** and

¹⁾ In the case of hydrazine hydrochlorides **18a,b,e**, no aqueous HCl solution was added.


Table. Yields of Enamino Ketones **4a,b**, **5**, **10**, 1H-Pyrazolamines **18a–c**, Hydrazine Derivatives **18a–i**, 2-Phenylethanamines **15a–e**, **17**, **21a–k**, **22a–g**, and α -Amino Alcohols **16**, **22a,b**, and **24a,b**

Reaction	R ¹	R ²	R ³	Yield [%]
2a → 3a → 4a	COOBn			52 ^{a)}
2b → 3b → 4b	Boc			83 ^{a)}
2b → 5				50
9 → 10				73
4a + 11a → 15a	COOBn	H	H	76
4b + 11a → 15b	Boc	H	H	44
4a + 11b → 15c	COOBn	H	Me	32
4a + 11c → 15d	COOBn	CN	H	73
4b + 11c → 15e	Boc	CN	H	20
10 + 11c → 16	COOBn	CN	H	77
4a + 12 → 17	Boc			27
4a + 18a → 21a/21'a	COOBn	H		98
4b + 18a → 21b/21'b	Boc	H		86
4a + 18b → 21c	COOBn	Ph		95
4a + 18c → 21d	COOBn	4-nitrophenyl		80
4a + 18d → 21e	COOBn	4-methoxyphenyl		70
4b + 18e → 21f	Boc	2-bromophenyl		90
4a + 18f → 21g	COOBn	pyridin-2-yl		83
4a + 18g → 21h	COOBn	pyrimidin-2-yl		89
4a + 18h → 21i	COOBn	6-chloropyridazin-3-yl		91
4b + 18h → 21j	Boc	6-chloropyridazin-3-yl		54
4a + 18i → 21k	COOBn	6-phenylpyridazin-3-yl		78
10 + 18b → 23a		Ph		92
10 + 18i → 23b		6-phenylpyridazin-3-yl		63
21a/21'a → 22a		H		92
21c → 22b		Ph		82
21d → 22c		4-aminophenyl		95
21e → 22d		4-methoxyphenyl		98
21g → 22e		pyridin-2-yl		85
21h → 22f		pyrimidin-2-yl		69
21k → 22g		6-phenylpyridazin-3-yl		70
23a → 24a		Ph		83
23b → 24b		6-phenylpyridazin-3-yl		64


a) Yield over two steps.

21'a,b, respectively. Deprotection of compounds **21c–e,g,h,k** by catalytic hydrogenation in the presence of 10% Pd/C afforded the free 2-phenyl-1-pyrazolyl-ethanamines **22a–g** in 70–98% yields. Similarly, 1-amino-1-pyrazolyl-propan-2-ols **24a,b** were prepared in two steps *via* **23a,b** from enamino ketone **10** (Scheme 3, Table).

All novel compounds were characterized by spectroscopic (IR, MS, HR-MS, ¹H- and ¹³C-NMR) methods and elemental analyses for C, H, and N. Compounds **3a,b**, **4a,b**, **5**, **10**, **15c,d**, **21c–e,h**, **23a**, **22a–g**, and **24a,b** were not prepared in analytically pure form. The identities of these compounds were confirmed by HR-EI-MS and ¹³C-NMR spectra or, in the case of **22a**, by FAB-MS and ¹³C-NMR spectra. The structure of compound **15b** was determined by X-ray diffraction (Fig. 2).

Scheme 2^{a)}^{a)} See Table for $R^1 - R^3$.*a)* EtOH, 37% aq. HCl soln. (1 equiv.), r.t. $\rightarrow$ reflux. *b)* EtOH, K_2CO_3 , reflux.

Conclusions. – Chiral enamino ketones **4a,b** and **10** are available in 3–4 steps from *N*-protected L-phenylalanines **1a,b** and L-threonine **6**, respectively. They were used efficiently as the key reagents in a two-step synthesis of 1-(heteroaryl)-2-phenylethanamines **22a–g** and 1-amino-1-(heteroaryl)propan-2-ols **24a,b**. Due to the wide applicability of 2-substituted alkyl 3-(dimethylamino)propenoates and related enamino ketones in heterocyclic synthesis and, since related enamino ketones could also be prepared from other commercially available α -amino acids *via* the corresponding *Weinreb* amides, this methodology could be extended also to the preparation of several other types of 1-(heteroaryl)alkanamines. In comparison with some known synthetic methods [14–16], especially with the ynone-mediated approach of *Knochel* and co-workers [14], the presented enamino ketone methodology is an additional and useful option for the efficient synthesis of chiral nonracemic 1-(heteroaryl)alkanamines.



a) EtOH, 37% aq. HCl soln. (1 equiv.), r.t. → reflux. b) H₂ (1 bar), EtOH and/or THF, 10% Pd/C, r.t.

The financial support from the *Slovenian Research Agency* through grants P0-0502-0103, P1-0179, and J1-6689-0103-04 is gratefully acknowledged. The authors wish to express their gratitude to the *Alexander von Humboldt Foundation*, Germany, for the donation of a *Büchi* medium-pressure liquid chromatograph. The diffraction data for compound **15b** were collected in the Laboratory of Inorganic Chemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Slovenia. We acknowledge the financial contribution of the Ministry of Science and Technology, Republic of Slovenia, through grants X-2000 and PS-511-103, which thus made the purchase of the apparatus possible.

Experimental Part

1. *General*. *N*-[(Benzyloxy)carbonyl]-L-phenylalanine (**1a**), *N*-[(*tert*-butoxy)carbonyl]-L-phenylalanine (**1b**), *N*-[(benzyloxy)carbonyl]-L-threonine (**6**), 1*H*-pyrazolamines **11a–c**, and hydrazines **18a–f** are commercially available (*Fluka AG* and *Sigma-Aldrich*). *Weinreb* amides **2a,b** [11] and **9** [12], 2-hydrazinopyrimidine (**18g**) [17], 6-chloro-3-hydrazinopyridazine (**18h**) [18], and 3-hydrazino-6-phenylpyridazine (**18i**) [19] were prepared according to the published procedures. All starting materials were commercially available (in most cases from *Fluka*) and purified following the standard techniques. Column chromatography (CC): silica gel 60 (0.04–0.06 mm; *Fluka*). Medium-pressure liquid chromatography




Fig. 2. ORTEP View of the asymmetric unit of compound **15b**. Arbitrary atom numbering. Ellipsoids at the 50% probability level.

(MPLC): Büchi isocratic system with detection²⁾; silica gel 60 (0.015–0.035 mm; Merck); 15 × 460 mm column (dry filled); backpressure 10–15 bar; UV detection at 254 nm; 100–150 mg of sample per run. TLC: aluminium foils coated with silica gel 60 F 254 (0.2 mm; Merck). M.p.: Kofler micro hot stage. Optical rotations: Perkin-Elmer-241-MC polarimeter. IR: Perkin-Elmer-Spectrum-BX-FTIR spectrophotometer; in cm^{-1} . ^1H -NMR (300 MHz) and ^{13}C -NMR (75.5 MHz): Bruker-Avance-DPX-300 spectrometer; δ in ppm rel. to Me_4Si as internal standard (=0 ppm), J in Hz. MS: Autospeck-Q (VG-Analytical) spectrometer; in m/z . Elemental analyses: Perkin-Elmer-CHN-2400-II analyzer.

2. Ethynyl Ketones **3a,b**: General Procedure. At -78° , 0.5M ($\text{HC}\equiv\text{CMgBr}$ in THF 80 ml, 40 mmol) was added slowly to the stirred soln. of **2** (10 mmol) in anh. THF (20 ml) under Ar, and the resulting mixture was stirred at -78° for 1 h and at r.t. for 12 h. The mixture was poured into cold (0°) 1M aq. NaHSO_4 (150 ml) and stirred for 1 h. THF was evaporated at 35 – 40° and the aq. residue extracted with Et_2O (2×150 ml). The combined org. phase was washed successively with 1M aq. NaHSO_4 (150 ml), sat. aq. NaHCO_3 soln. (150 ml), and brine (150 ml), dried (Na_2SO_4), and evaporated and the residue purified by CC (AcOEt/hexanes): **3a,b**.

Benzyl [(1*S*)-1-Benzyl-2-oxobut-3-ynyl]carbamate (**3a**). From **2a** (3.2 g, 9.3 mmol), after CC (AcOEt/hexanes 1:3): 1.74 g (61%) of **3a**. Oil. $[\alpha]_{\text{D}}^{25} = +1.27$ ($c = 1.05$, CHCl_3). IR (NaCl): 3404, 3270, 3031, 2093 ($\text{C}\equiv\text{C}$), 1687 ($\text{C}=\text{O}$), 1497, 1455, 1254, 1045, 697. ^1H -NMR (CDCl_3): 3.20 (*dd*, $J = 6.0$, 14.3, 1 H of PhCH_2); 3.29 (*dd*, $J = 5.7$, 14.3, 1 H of PhCH_2); 3.39 (*s*, $\text{H}-\text{C}(1)$); 4.71–4.80 (*m*, $\text{H}-\text{C}(4)$); 5.09 (*s*, PhCH_2O); 5.22 (*d*, $J = 7.2$, NH); 7.09–7.15 (*m*, 2 H of Ph); 7.22–7.40 (*m*, 8 H of Ph). ^{13}C -NMR (CDCl_3): 37.1; 62.8; 67.5; 80.1; 83.1; 127.7; 128.5; 128.7; 128.9; 129.1; 129.8; 135.5; 136.6; 156.1; 185.4. EI-MS: 307 (M^+). EI-HR-MS: 307.12060 ($\text{C}_{19}\text{H}_{17}\text{N}_1\text{O}_3^+$, M^+ ; calc. 307.120844).

tert-Butyl [(1*S*)-1-Benzyl-2-oxobut-3-ynyl]carbamate (**3b**). From **2b** (2.5 g, 8.1 mmol), after CC (AcOEt/hexanes 1:5): 2.0 g (90%) of **3b**. Oil. $[\alpha]_{\text{D}}^{25} = +8.66$ ($c = 1.73$, CHCl_3). IR (NaCl): 3354, 3268, 2979, 2093 ($\text{C}\equiv\text{C}$), 1711 ($\text{C}=\text{O}$), 1688 ($\text{C}=\text{O}$), 1497, 1456, 1367, 1252, 1165, 1048, 700. ^1H -NMR (CDCl_3): 1.41 (*s*, *t*-BuO); 3.16 (*dd*, $J = 5.7$, 14.3, $\text{H}_a-\text{C}(5)$); 3.27 (*dd*, $J = 5.7$, 14.3, $\text{H}_b-\text{C}(5)$); 3.39 (*s*,

²⁾ Donation of the Alexander von Humboldt Foundation, Germany.

H–C(1)); 4.62–4.73 (*m*, H–C(4)); 4.97 (*d*, $J=6.8$, NH); 7.13–7.19 (*m*, 2 H of Ph); 7.21–7.39 (*m*, 3 H of Ph). ^{13}C -NMR (CDCl_3): 28.7; 37.2; 62.4; 80.3; 80.6; 82.6; 127.6; 129.0; 129.8; 135.7; 155.4; 186.0. FAB-MS: 274 ($[M+H]^+$).

3. Alkyl [(1*S*,3*E*)-1-Benzyl-4-(diethylamino)-2-oxobut-3-enyl]carbamates **4a,b**: General Procedure Et_2NH (0.73 ml, 5.2 mmol) was added to a cooled (0°) soln. of **3a,b** (5 mmol) in CH_2Cl_2 (35 ml), and the soln. was stirred at r.t. for 12 h. Volatile components were evaporated, and the residue was purified by CC (AcOEt/hexanes 2:1): **4a,b**.

Benzyl [(1*S*,3*E*)-1-Benzyl-4-(diethylamino)-2-oxobut-3-enyl]carbamate (**4a**). From **3a** (1.2 g, 3.9 mmol) and Et_2NH (0.55 ml): 1.28 g (86%) of **4a**. Oil. $[\alpha]_{\text{D}}^{21} = +34.4$ ($c=1.13$, CHCl_3). IR (NaCl): 3397, 3292, 2976, 1717 (C=O), 1649, 1565, 1497, 1365, 1281, 1045, 699. ^1H -NMR (CDCl_3): 1.03, 1.18 (2 *m*, 1:1, 2 MeCH_2); 2.92–3.16 (*m*, MeCH_2 , $\text{H}_\alpha\text{--C}(5)$, $\text{H}_\beta\text{--C}(5)$); 3.21 (br. *s*, MeCH_2); 4.49–4.62 (*m*, H–C(4)); 4.85 (*d*, $J=12.4$, H–C(2)); 5.09 (*s*, PhCH_2O); 5.80 (br. *d*, $J=6.8$, NH); 7.09–7.24 (*m*, Ph); 7.28–7.39 (*m*, Ph); 7.49 (br. *s*, H–C(1)). ^{13}C -NMR (CDCl_3): 11.8; 15.0; 40.4; 43.0; 50.9; 66.8; 126.8; 128.28; 128.30; 128.6; 128.8; 130.0; 137.2; 137.9; 151.8; 156.1; 193.5. EI-MS: 380 (M^+). EI-HR-MS: 380.210870 ($\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_3^+$, M^+ ; calc. 380.209993).

tert-Butyl [(1*S*,3*E*)-1-Benzyl-4-(diethylamino)-2-oxobut-3-enyl]carbamate (**4b**). From **3b** (1.7 g, 6.2 mmol) and Et_2NH (0.9 ml): 1.98 g (92%) of **4b**. Oil. $[\alpha]_{\text{D}}^{21} = +32.3$ ($c=0.75$, CHCl_3). IR (NaCl): 3412, 2976, 2932, 1709 (C=O), 1649, 1568, 1468, 1366, 1283, 1170, 1047, 776, 701. ^1H -NMR (CDCl_3): 1.04, 1.17 (2 *m*, 1:1, 2 MeCH_2); 1.41 (*s*, *t*-Bu); 2.91–3.14 (*m*, MeCH_2 , PhCH_2); 3.21 (br. *s*, MeCH_2); 4.45–4.56 (*m*, H–C(4)); 4.85 (*d*, $J=12.8$, H–C(2)); 5.53 (br. *d*, $J=7.2$, NH); 7.12–7.26 (*m*, Ph); 7.48 (br. *s*, H–C(1)). ^{13}C -NMR (CDCl_3): 11.8; 15.0; 28.8; 40.6; 42.9; 50.9; 79.4; 126.7; 128.5; 130.0; 138.2; 151.7; 155.7; 194.1. EI-MS: 346 (M^+). EI-HR-MS: 346.225013 ($\text{C}_{20}\text{H}_{30}\text{N}_2\text{O}_3^+$, M^+ ; calc. 346.225643).

4. N-Methoxy-N-methyl(enamino) Ketones **5** and **10**: General Procedure. At -78° , 0.5M ($\text{HC}\equiv\text{CMgBr}$ in THF 80 ml, 40 mmol) was added slowly to a stirred soln. of **2b** or **9** (10 mmol) in anh. THF (20 ml) under Ar, and the mixture was stirred at -78° for 1 h and at r.t. for 12 h. The mixture was poured into cold (0°) sat. aq. NH_4Cl soln. (100 ml) and stirred at r.t. for 1 h. THF was then evaporated at ca. 30° , and the aq. residue was extracted with Et_2O (2×150 ml). The combined org. phase was washed successively with 1M aq. NaHSO_4 (150 ml), sat. aq. NaHCO_3 soln. (150 ml), and brine (150 ml), dried (Na_2SO_4), and evaporated and the residue purified by CC (AcOEt/hexanes 1:1): **5** or **10**.

tert-Butyl [(1*S*,3*E*)-4-[Methoxy(methyl)amino]-2-oxobut-3-enyl]carbamate (**5**). From **2b** (2.5 g, 8.1 mmol): 1.35 g (50%) of **5**. Oil. $[\alpha]_{\text{D}}^{21} = +100.8$ ($c=0.52$, CHCl_3). IR (NaCl): 3414, 3323, 2975, 1709 (C=O), 1657, 1578, 1493, 1366, 1170, 1046, 1012, 701. ^1H -NMR (CDCl_3): 1.41 (*s*, *t*-BuO); 3.00–3.06 (*m*, PhCH_2); 3.10 (*s*, MeN); 3.58 (*s*, MeO); 4.51–4.59 (*m*, H–C(4)); 5.26 (*d*, $J=12.8$, H–C(2)); 5.42 (*d*, $J=7.5$, NH); 7.15–7.29 (*m*, Ph); 7.35 (*d*, $J=12.4$, H–C(1)). ^{13}C -NMR (CDCl_3): 28.8; 39.8; 39.9; 59.2; 60.1; 79.6; 95.1; 126.8; 128.6; 130.0; 137.7; 148.4; 155.6; 195.2. EI-MS: 335 ($[M+H]^+$). FAB-MS: 335 ($[M+H]^+$). EI-HR-MS: 335.198060 ($\text{C}_{18}\text{H}_{27}\text{N}_2\text{O}_4^+$, $[M+H]^+$; calc. 335.197083).

Benzyl (4*S*,5*R*)-4-[(2*E*)-3-[Methoxy(methyl)amino]prop-2-enoyl]-2,2,5-trimethyloxazolidine-3-carboxylate (**10**). From **9** (4.77 g, 14.2 mmol): 3.73 g (73%) of **10**. Oil. $[\alpha]_{\text{D}}^{25} = -35.7$ ($c=1.00$, CHCl_3). IR (NaCl): 2982, 1708 (C=O), 1663, 1579, 1410, 1350, 1123, 1072, 988, 696. ^1H -NMR ($(\text{D}_6)\text{DMSO}$, 80°): 1.30 (*d*, $J=6.0$, Me–C(5)); 1.52, 1.55 (2*s*, 1:1, 2 Me–C(2)); 3.17 (*s*, MeN); 3.58 (*s*, MeO); 3.89–3.99 (*m*, H–C(5)); 4.07 (*d*, $J=7.5$, H–C(4)); 4.98 (*s*, PhCH_2O); 5.30 (*d*, $J=12.4$, $\text{CH}=\text{CHNMe}$); 7.21–7.36 (*m*, Ph); 7.48 (*d*, $J=12.4$, $\text{CH}=\text{CHNMe}$). ^{13}C -NMR ($(\text{D}_6)\text{DMSO}$, 80°): 19.9; 25.4; 27.7; 39.9; 60.0; 66.8; 71.1; 75.3; 93.7; 95.0; 128.3; 128.4; 129.0; 137.4; 149.0; 152.5; 192.6. EI-MS: 363 ($[M+H]^+$). EI-HR-MS: 363.193002 ($\text{C}_{19}\text{H}_{27}\text{N}_2\text{O}_5^+$, $[M+H]^+$; calc. 363.191997).

5. Compounds **15a–e**, **21a–k**, and **23a,b**. General Procedure A (G.P. A). A mixture of **4a,b** or **10** (0.5 mmol), hydrazine derivative **18** (0.5 mmol), EtOH (4 ml), and 37% aq. HCl soln.¹⁾ (2 drops, ca. 0.6 mmol) was slowly heated up and then refluxed for 1.5–6 h. After cooling the precipitate was collected by filtration and washed with cold (0°) EtOH and Et_2O . Compounds **21g,i–k** and **23b** were prepared in this manner.

General Procedure B (G.P. B). A mixture of **4a,b** or **10** (0.5 mmol), 1*H*-pyrazolamine **11** or hydrazine derivative **18a–i** (0.5 mmol), EtOH (4 ml), and 37% aq. HCl¹⁾ soln. (2 drops, ca. 0.6 mmol) was stirred at $20\text{--}80^\circ$ for 2–48 h. Volatile components were evaporated, and the residue was purified by CC. Compounds **15a–e**, **21a–f,h**, and **23a** were prepared in this manner.

Benzyl [(1*S*)-2-Phenyl-1-(pyrazolo[1,5-*a*]pyrimidin-7-yl)ethyl]carbamate (15a). From **4a** (0.190 g, 0.5 mmol) and **11a** (0.042 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 5 h). CC (AcOEt/hexanes 1:2) gave 0.142 g (76%) of **15a**. M.p. 155–157° (from EtOH). $[\alpha]_{\text{D}}^{22} = +64.7$ ($c = 0.44$, CHCl₃). IR (KBr): 3311, 1683 (C=O), 1615, 1537, 1454, 1272, 1089, 1057, 1022, 745, 703. ¹H-NMR (CDCl₃): 3.37 (*dd*, $J = 7.1$, 13.3, H_a–C(2)); 3.53 (*dd*, $J = 8.1$, 13.3, H_b–C(2)); 5.01, 5.09 (*2d*, $J = 12.1$, PhCH₂O); 5.40–5.51 (*m*, H–C(1)); 6.42 (*d*, $J = 4.1$, H–C(6')); 6.57 (*br. d*, $J = 9.0$, NH); 6.76 (*d*, $J = 2.3$, H–C(3')); 6.90–6.99 (*m*, 2 H of Ph); 7.15–7.22 (*m*, 3 H of Ph); 7.26–7.37 (*m*, Ph); 8.18 (*d*, $J = 2.3$, H–C(2')); 8.29 (*d*, $J = 4.1$, H–C(5')). ¹³C-NMR (CDCl₃): 38.1; 54.8; 67.1; 97.0; 106.4; 127.0; 128.1; 128.2; 128.5; 128.6; 129.0; 136.1; 136.4; 144.5; 145.9; 149.0; 149.3; 155.6. EI-MS: 372 (*M*⁺). EI-HR-MS: 372.159560 (C₂₂H₂₀N₄O₂⁺, *M*⁺; calc. 372.158626). Anal. calc. for C₂₂H₂₀N₄O₂ (372.42): C 70.95, H 5.41, N 15.04; found: C 70.80, H 5.47, N 15.08.

tert-Butyl [(1*S*)-2-Phenyl-1-(pyrazolo[1,5-*a*]pyrimidin-7-yl)ethyl]carbamate (15b). From **4b** (0.173 g, 0.5 mmol) and **11a** (0.042 g, 0.5 mmol) by *G.P. B* (stirring at 20° for 48 h). CC (AcOEt/hexanes 1:2) gave 0.074 g (44%) of **15b**. M.p. 141–144°. $[\alpha]_{\text{D}}^{24} = +54.6$ ($c = 0.50$, CHCl₃). IR (KBr): 3346, 1686 (C=O), 1616, 1526, 1456, 1274, 1169, 820, 704. ¹H-NMR (CDCl₃): 1.38 (*s*, *t*-BuO); 3.32 (*dd*, $J = 6.8$, 13.2, H_a–C(2)); 3.51 (*dd*, $J = 7.9$, 13.2, H_b–C(2)); 5.37–5.47 (*m*, H–C(1)); 6.22 (*br. d*, $J = 6.4$, NH); 6.43 (*br. d*, $J = 3.0$, H–C(6')); 6.76 (*d*, $J = 2.3$, H–C(3')); 6.92–7.00 (*m*, 2 H of Ph); 7.16–7.22 (*m*, 3 H of Ph); 8.20 (*d*, $J = 2.3$, H–C(2')); 8.30 (*br. d*, $J = 3.0$, H–C(5')). ¹³C-NMR (CDCl₃): 28.3; 38.2; 54.1; 80.2; 96.9; 106.3; 126.9; 128.5; 129.0; 136.6; 144.5; 146.5; 149.0; 149.3; 154.9. Anal. calc. for C₁₉H₂₂N₄O₂ (338.40): C 67.44, H 6.55, N 16.56; found: C 67.71, H 6.77, N 16.52.

Benzyl [(1*S*)-1-(2-Methylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-phenylethyl]carbamate (15c). From **4a** and **11b** (0.049 g, 0.5 mmol) by *G.P. B* (stirring at 20° for 48 h). CC (AcOEt/hexanes 2:3) gave 0.060 g (32%) of **15c**. M.p. 169–173°. $[\alpha]_{\text{D}}^{25} = +49.9$ ($c = 0.40$, CHCl₃). IR (KBr): 3458, 3309, 1685, 1613, 1536, 1268, 740, 696. ¹H-NMR (CDCl₃): 2.56 (*s*, Me–C(2')); 3.36 (*dd*, $J = 7.0$, 13.2, H_a–C(2)); 3.52 (*dd*, $J = 7.9$, 13.2, H_b–C(2)); 5.02, 5.10 (*2d*, $J = 12.1$, PhCH₂O); 5.34–5.45 (*m*, H–C(1)); 6.31 (*d*, $J = 4.1$, H–C(6')); 6.51 (*s*, H–C(3')); 6.64 (*br. d*, $J = 8.7$, NH); 6.90–7.00 (*m*, 2 H of Ph); 7.14–7.22 (*m*, 3 H of Ph); 7.27–7.40 (*m*, Ph); 8.20 (*d*, $J = 4.1$, H–C(5')). ¹³C-NMR (CDCl₃): 15.2; 38.6; 55.3; 67.5; 77.3; 96.6; 106.0; 127.4; 128.6; 129.0; 129.5; 136.6; 136.9; 137.2; 145.6; 149.1; 150.5; 155.4; 156.1. EI-MS: 386 (*M*⁺). EI-HR-MS: 386.175060 (C₂₃H₂₂N₄O₂⁺, *M*⁺; calc. 386.174276).

Benzyl [(1*S*)-1-(3-Cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-phenylethyl]carbamate (15d). From **4a** (0.190 g, 0.5 mmol) and **11c** (0.054 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 4 h). CC (CHCl₃/MeOH 60:1) gave 0.145 g (73%) of **15d**. M.p. 85–89°. $[\alpha]_{\text{D}}^{21} = +55.46$ ($c = 0.61$, CHCl₃). IR (KBr): 3343, 2230 (C≡N), 1696 (C=O), 1620, 1552, 1527, 1264, 1217, 1057, 737, 698. ¹H-NMR (CDCl₃): 3.31 (*dd*, $J = 7.3$, 13.4, H_a–C(2)); 3.48 (*dd*, $J = 7.4$, 13.7, H_b–C(2)); 4.97–5.10 (*m*, PhCH₂O); 5.51–5.61 (*m*, H–C(1)); 6.06 (*br. d*, $J = 8.6$, NH); 6.73 (*d*, $J = 4.5$, H–C(6')); 6.91–6.97 (*m*, 2 H of Ph); 7.20–7.25 (*m*, 3 H of Ph); 7.26–7.39 (*m*, Ph); 8.46 (*s*, H–C(2')); 8.55 (*d*, $J = 4.5$, H–C(5')). ¹³C-NMR (CDCl₃): 38.4; 54.4; 67.8; 83.9; 109.3; 112.9; 127.9; 128.6; 128.8; 129.0; 129.25; 129.29; 135.9; 136.2; 147.5; 149.1; 151.1; 153.1; 155.9. EI-MS: 397 (*M*⁺). FAB-MS: 398 ([*M*+H]⁺). EI-HR-MS: 397.154250 (C₂₃H₁₉N₅O₂⁺, *M*⁺; calc. 397.153875).

tert-Butyl [(1*S*)-1-(3-Cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-phenylethyl]carbamate (15e). From **4b** (0.173 g, 0.5 mmol) and **11c** (0.054 g, 0.5 mmol) by *G.P. B* (stirring at 20° for 24 h). CC (AcOEt/hexanes 1:2) gave 0.036 g (20%) of **15e**. M.p. 149–152°. $[\alpha]_{\text{D}}^{24} = +55.7$ ($c = 0.50$, CHCl₃). IR (KBr): 3362, 2231 (C≡N), 1712 (C=O), 1620, 1553, 1518, 1368, 1250, 1168, 701. ¹H-NMR (CDCl₃): 1.38 (*s*, *t*-BuO); 3.20–3.32 (*m*, H_a–C(2)); 3.46 (*dd*, $J = 7.2$, 13.6, H_b–C(2)); 5.49–5.58 (*m*, H–C(1)); 5.73 (*br. s*, NH); 6.75 (*br. d*, $J = 3.8$, H–C(6')); 6.92–7.01 (*m*, 2 H of Ph); 7.18–7.25 (*m*, 3 H of Ph); 8.47 (*s*, H–C(2')); 8.57 (*br. d*, $J = 3.8$, H–C(5')). ¹³C-NMR (CDCl₃): 28.7; 38.6; 53.9; 81.3; 83.9; 109.1; 113.0; 127.9; 129.3; 192.4; 136.1; 147.6; 149.9; 151.2; 153.1; 155.2. Anal. calc. for C₂₀H₂₁N₅O₂ (363.41): C 66.10, H 5.82, N 19.27; found: C 66.04, H 6.08, N 18.98.

Benzyl [(1*S*)-2-Phenyl-1-(1*H*-pyrazol-5-yl)ethyl]carbamate (21a) and Benzyl [(1*S*)-2-Phenyl-1-(1*H*-pyrazol-3-yl)ethyl]carbamate (21'a). From **4a** (0.190 g, 0.5 mmol) and **18a** (0.035 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 6 h). CC (CHCl₃/MeOH 30:1) gave 0.158 g (98%) of **21a/21'a** 72:28. M.p. 122–138° (CH₂Cl₂/hexane). $[\alpha]_{\text{D}}^{22} = -21.7$ ($c = 0.62$, CHCl₃). IR (KBr): 3356, 1693 (C=O), 1537, 1455, 1249, 1040, 744, 701. ¹H-NMR (CDCl₃): 3.18 (*d*, $J = 6.0$, H–C(2)); 4.97–5.21 (*m*, H–C(1)); 5.08 (*s*,

PhCH₂O); 5.60 (br. s, NH); 6.05 (s, H–C(4')); 6.75 (br. s, H–N(1')); 7.00–7.14 (m, 2 H of Ph); 7.15–7.24 (m, 3 H of Ph); 7.27–7.47 (m, Ph, H–C(3')). ¹H-NMR ((D₆)DMSO): 2.95 (dd, *J* = 9.8, 13.6, H_a–C(2)); 3.03–3.16 (m, H_b–C(2)); 4.82–5.01 (m, PhCH₂O, H–C(1)); 6.18 (s, H–C(4')); 7.14–7.38 (m, 2 Ph); 7.61 (s, H–C(3')); 7.43 (br. s, NH (**21a**)); 7.64 (br. s, NH (**21a**)); 12.52 (br. s, H–N(1') (**21a**)); 12.65 (br. s, H–N(1') (**21a**)). EI-MS: 322 ([*M* + H]⁺). EI-HR-MS: 322.156050 (C₁₉H₂₀N₃O₂⁺, [*M* + H]⁺); calc. 322.155552). Anal. calc. for C₁₉H₁₉N₃O₂ (321.37): C 71.07, H 5.96, N 13.08; found: C 70.95, H 6.04, N 13.08.

tert-Butyl [(1*S*)-2-Phenyl-1-(1*H*-pyrazol-5-yl)ethyl]carbamate (**21b**) and tert-Butyl [(1*S*)-2-Phenyl-1-(1*H*-pyrazol-3-yl)ethyl]carbamate (**21b'**). From **4b** (0.173 g, 0.5 mmol) and **18a** (0.034 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 6 h). CC (CHCl₃/MeOH 40:1) gave 0.124 g (86%) of **21b/21b'** 87:13. M.p. 113–115°. [*α*]_D²¹ = –28.7 (*c* = 0.65, CHCl₃). IR (KBr): 3379, 2978, 1690 (C=O), 1518, 1366, 1247, 1171, 1023, 800, 700. ¹H-NMR (CDCl₃): 1.40 (s, *t*-BuO); 3.16 (d, *J* = 5.7, H–C(2)); 5.06 (br. d, *J* = 5.7, H–C(1)); 5.20 (br. s, NH); 6.05 (s, H–C(4')); 6.40 (br. s, H–N(1')); 7.08–7.14 (m, 2 H of Ph); 7.15–7.28 (m, 3 H of Ph); 7.45 (d, *J* = 1.9, H–C(3')). ¹H-NMR ((D₆)DMSO): 1.19 (s, *t*-BuO (**21b'**)); 1.29 (s, *t*-BuO (**21b**)); 2.92 (dd, *J* = 9.4, 13.2, H_a–C(2)); 3.05 (dd, *J* = 5.3, 13.2, H_b–C(2)); 4.82 (br. s, H–C(1)); 6.16 (s, H–C(4') (**21b**)); 6.67 (br. s, H–C(4') (**21b'**)); 7.02–7.37 (m, Ph, H–C(3')); 7.59 (s, NH); 12.48 (br. s, H–N(1') (**21b**)); 12.56 (br. s, H–N(1') (**21b'**)). ¹³C-NMR (CDCl₃): 28.3; 41.7 (**21b**); 44.4 (**21b'**); 49.8 (**21b**); 52.1 (**21b'**); 79.7; 103.2; 126.4; 128.2; 129.5; 131.8; 137.5; 150.3 (**21b**); 151.1 (**21b'**); 155.5 (**21b'**); 156.1 (**21b**). Anal. calc. for C₁₆H₂₁N₃O₂ (287.36): C 66.88, H 7.37, N 14.62; found: C 67.18, H 7.61, N 14.61.

Benzyl [(1*S*)-2-Phenyl-1-(1-phenyl-1*H*-pyrazol-5-yl)ethyl]carbamate (**21c**). From **4a** (0.190 g, 0.5 mmol) and **18b** (0.073 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 6 h). CC (AcOEt/hexanes 1:2) gave 0.189 g (95%) of **21c**. Oil. [*α*]_D²¹ = +12.2 (*c* = 1.50, CHCl₃). IR (NaCl): 3310, 3063, 3031, 1713 (C=O), 1599, 1530, 1503, 1454, 1399, 1250, 1028, 697. ¹H-NMR (CDCl₃): 2.90 (dd, *J* = 7.5, 13.3, H_a–C(2)); 3.00 (dd, *J* = 5.8, 13.2, H_b–C(2)); 4.95–5.20 (m, H–C(1), NH, PhCH₂O); 6.31 (d, *J* = 1.9, H–C(4')); 6.83–6.89 (m, 2 H of Ph); 7.11–7.23 (m, 5 H of Ph); 7.26–7.40 (m, 8 H of Ph); 7.60 (d, *J* = 1.9, H–C(3')). ¹³C-NMR (CDCl₃): 42.7; 49.4; 67.4; 104.9; 126.3; 127.3; 128.5; 128.6; 128.81; 128.84; 129.0; 129.5; 129.7; 136.4; 136.6; 139.6; 140.3; 144.3; 155.6. EI-MS: 398 ([*M* + H]⁺). FAB-MS: 398 ([*M* + H]⁺). EI-HR-MS: 398.187950 (C₂₅H₂₄N₃O₂⁺, [*M* + H]⁺); calc. 398.186852).

Benzyl [(1*S*)-1-[1-(4-Nitrophenyl)-1*H*-pyrazol-5-yl]-2-phenylethyl]carbamate (**21d**). From **4a** (0.190 g, 0.5 mmol), **18c** (0.077 g, 0.5 mmol), and 37% aq. HCl soln. (2 drops, ca. 0.6 mmol) by *G.P. B* (stirring at 80° for 1.5 h). CC (AcOEt/hexanes 1:2) gave 0.177 g (80%) of **21d**. Oil. [*α*]_D²⁴ = +71.2 (*c* = 0.612, CHCl₃). IR (KBr): 3317, 3031, 1711 (C=O), 1598, 1522, 1503, 1342, 1246, 1111, 1026, 855, 698. ¹H-NMR (CDCl₃): 2.89 (dd, *J* = 8.7, 12.8, H_a–C(2)); 3.10 (dd, *J* = 4.9, 13.2, H_b–C(2)); 5.06 (s, PhCH₂O); 5.08–5.20 (m, H–C(1), NH); 6.45 (d, *J* = 1.9, H–C(4')); 6.79–6.84 (m, 2 H of C₆H₄); 7.08–7.21 (m, 4 H of Ph); 7.27–7.41 (m, 6 H of Ph); 7.67 (d, *J* = 1.9, H–C(3')). ¹³C-NMR (CDCl₃): 43.3; 49.6; 67.5; 106.2; 124.8; 126.5; 127.6; 128.5; 128.8; 128.95; 129.05; 129.5; 136.1; 136.5; 141.6; 144.6; 145.2; 147.1; 155.9. EI-MS: 443 ([*M* + H]⁺). EI-HR-MS: 443.172680 (C₂₅H₂₃N₄O₄⁺, [*M* + H]⁺); calc. 443.171931).

Benzyl [(1*S*)-1-[1-(4-Methoxyphenyl)-1*H*-pyrazol-5-yl]-2-phenylethyl]carbamate (**21e**). From **4a** (0.190 g, 0.5 mmol) and **18d** (0.087 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 3 h). CC (AcOEt/hexanes 1:2) gave 0.150 g (70%) of **21e**. Oil. [*α*]_D²¹ = +11.6 (*c* = 1.74, CHCl₃). IR (NaCl): 3312, 3031, 2936, 1716 (C=O), 1518, 1455, 1251, 1028, 837, 699. ¹H-NMR (CDCl₃): 2.91 (dd, *J* = 7.5, 13.2, H_a–C(2)); 2.96–3.06 (m, H_b–C(2)); 3.82 (s, MeO); 5.03 (m, H–C(1), NH, PhCH₂O); 6.28 (d, *J* = 1.9, H–C(4')); 6.80–6.91 (m, 2 H of C₆H₄); 7.00–7.11 (m, 2 H of Ph); 7.13–7.21 (m, 2 H of C₆H₄); 7.26–7.40 (m, Ph); 7.57 (d, *J* = 1.9, H–C(3')). ¹³C-NMR (CDCl₃): 42.7; 49.4; 55.9; 67.3; 104.4; 114.6; 127.3; 127.8; 128.5; 128.6; 128.8; 128.9; 129.7; 132.6; 136.5; 136.6; 139.9; 144.3; 155.6; 159.9. EI-MS: 428 ([*M* + H]⁺). HR-MS: 428.198300 (C₂₆H₂₆N₃O₃⁺, [*M* + H]⁺); calc. 428.197417).

tert-Butyl [(1*S*)-1-[1-(2-Bromophenyl)-1*H*-pyrazol-5-yl]-2-phenylethyl]carbamate (**21f**). From **4b** (0.173 g, 0.5 mmol) and **18e** (0.112 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 2 h). CC (AcOEt/hexanes 1:2) gave 0.199 g (90%) of **21f**. M.p. 39–45°. [*α*]_D²¹ = –57.4 (*c* = 0.53, CHCl₃). IR (KBr): 3273, 2976, 1703 (C=O), 1494, 1455, 1366, 1248, 1169, 1019, 928, 763, 698. ¹H-NMR ((D₆)DMSO, 80°): 1.16 (s, *t*-BuO); 2.93 (br. d, *J* = 8.3, CH₂(2)); 4.53–4.63 (m, H–C(1)); 6.51 (d, *J* = 1.5, H–C(4')); 6.88 (br. s, NH); 6.94–7.02 (m,

2 H of Ph); 7.10–7.24 (*m*, 3 H of Ph, 1 H of C₆H₄); 7.41–7.52 (*m*, 2 H of C₆H₄); 7.58 (*d*, *J* = 1.5, H–C(3'')); 7.76–7.82 (*m*, 1 H of C₆H₄). Anal. calc. for C₂₂H₂₄BrN₃O₂ (442.35): C 59.73; H 5.47; N 9.50; found: C 59.66, H 5.60, N 9.46.

Benzyl {(1*S*)-2-Phenyl-1-[1-(pyridin-2-yl)-1*H*-pyrazol-5-yl]ethyl}carbamate (**21g**). From **4a** (0.190 g, 0.5 mmol), **18f** (0.054 g, 0.5 mmol), and 37% aq. HCl soln. (2 drops, *ca.* 0.6 mmol) by *G.P. A* (reflux for 3 h): 0.165 g (83%) of **21g**. M.p. 165–166°. [α]_D²⁴ = +20.3 (*c* = 0.80, CHCl₃). IR (KBr): 3334, 1687 (C=O), 1594, 1543, 1475, 1436, 1387, 1261, 1028, 801, 779, 743, 699. ¹H-NMR (CDCl₃): 3.08 (*dd*, *J* = 7.9, 13.7, H_a–C(2)); 3.17 (*dd*, *J* = 7.4, 13.7, H_b–C(2)); 5.04 (*s*, PhCH₂O); 5.74–5.85 (*m*, H–C(1)); 6.21 (*d*, *J* = 1.5, H–C(4'')); 6.63 (*br. d*, *J* = 7.2, NH); 6.99–7.06 (*m*, 2 H of Ph); 7.13–7.22 (*m*, 3 H of Ph); 7.25 (*ddd*, *J* = 1.0, 5.0, 8.3, H–C(5'')); 7.26–7.37 (*m*, 5 H of Ph); 7.55 (*d*, *J* = 1.5, H–C(3'')); 7.86 (*dt*, *J* = 1.8, 8.2, H–C(4'')); 7.99 (*br. d*, *J* = 8.1, H–C(3'')); 8.49 (*br. d*, *J* = 4.5, H–C(3'')). ¹³C-NMR (CDCl₃): 41.3; 50.6; 67.0; 109.6; 116.8; 122.1; 127.0; 128.4; 128.7; 128.9; 129.6; 137.0; 137.9; 139.4; 141.1; 144.7; 147.6; 153.7; 156.1. EI-MS: 398 (*M*⁺). EI-HR-MS: 398.175250 (C₂₄H₂₂N₄O₂⁺, *M*⁺; calc. 398.174276). Anal. calc. for C₂₄H₂₂N₄O₂ (398.46): C 72.34, H 5.75, N 14.06; found: C 72.61, H 5.63, N 13.72.

Benzyl {(1*S*)-2-Phenyl-1-[1-(pyrimidin-2-yl)-1*H*-pyrazol-5-yl]ethyl}carbamate (**21h**). From **4a** (0.190 g, 0.5 mmol), **18g** (0.055 g, 0.5 mmol), and 37% aq. HCl soln. (2 drops, *ca.* 0.6 mmol) by *G.P. B* (stirring at 80° for 3 h). CC (AcOEt) gave 0.177 g (89%) of **21h**. M.p. 139–142°. [α]_D²¹ = +23.9 (*c* = 1.00, CHCl₃). IR (KBr): 3442, 3329, 1696 (C=O), 1573, 1541, 1422, 1258, 1027, 921, 737, 696. ¹H-NMR (CDCl₃): 2.98–3.13 (*m*, H_a–C(2)); 3.22 (*dd*, *J* = 6.0, 13.9, H_b–C(2)); 5.03 (*s*, PhCH₂O); 5.82 (*br. d*, *J* = 7.1, NH); 5.98–6.07 (*m*, H–C(1)); 6.28 (*d*, *J* = 1.5, H–C(4'')); 7.03–7.11 (*m*, 2 H of Ph); 7.17–7.37 (*m*, 8 H of Ph, H–C(5'')); 7.68 (*d*, *J* = 1.5, H–C(3'')); 8.81 (*d*, *J* = 4.5, H–C(4''), H–C(6'')). ¹³C-NMR (CDCl₃): 41.1; 50.1; 66.7; 109.4; 118.6; 126.7; 128.0; 128.37; 128.41; 129.2; 136.4; 136.8; 142.0; 146.1; 155.5; 157.2; 158.6. EI-MS: 399 (*M*⁺). EI-HR-MS: 399.170620 (C₂₃H₂₁N₅O₂⁺, *M*⁺; calc. 399.169525).

Benzyl {(1*S*)-1-[1-(6-Chloropyridazin-3-yl)-1*H*-pyrazol-5-yl]-2-phenylethyl}carbamate (**21i**). From **4a** (0.190 g, 0.5 mmol), **18h** (0.073 mg, 0.5 mmol), and 37% aq. HCl soln. (2 drops, *ca.* 0.6 mmol) by *G.P. A* (reflux for 3 h): 0.197 g (91%) of **21i**. M.p. 181–184° (EtOH). [α]_D²⁴ = +22.5 (*c* = 1.00, CHCl₃). IR (KBr): 3338, 1694 (C=O), 1539, 1467, 1425, 1256, 1027, 921, 698. ¹H-NMR (CDCl₃): 3.11–3.22 (*m*, H_a–C(2)); 3.30 (*dd*, *J* = 6.4, 13.9, H_b–C(2)); 5.00 (*s*, PhCH₂O); 5.75–5.86 (*m*, H–C(1)); 6.11 (*br. d*, *J* = 7.9, NH); 6.33 (*d*, *J* = 1.5, H–C(4'')); 7.07–7.13 (*m*, 2 H of Ph); 7.18–7.36 (*m*, 8 H of Ph); 7.63 (*br. d*, *J* = 8.7, H–C(5'')); 7.64 (*d*, *J* = 1.5, H–C(3'')); 8.23 (*d*, *J* = 8.7, H–C(4'')). ¹³C-NMR (CDCl₃): 41.0; 50.8; 67.1; 110.7; 123.7; 127.2; 128.4; 128.85; 128.88; 129.7; 131.2; 136.8; 137.4; 142.8; 146.3; 155.0; 156.0; 156.1. EI-MS: 433 (*M*⁺). Anal. calc. for C₂₃H₂₀ClN₅O₂ (433.89): C 63.67, H 4.65, N 16.14; found: C 63.56, H 4.72, N 16.23.

tert-Butyl {(1*S*)-1-[1-(6-Chloropyridazin-3-yl)-1*H*-pyrazol-5-yl]-2-phenylethyl}carbamate (**21j**). From **4b** (0.173 g, 0.5 mmol), **18h** (0.072 g, 0.5 mmol), and 37% aq. HCl soln. (2 drops, *ca.* 0.6 mmol) by *G.P. A* (reflux for 6 h): 0.108 g (54%) of **21j**. M.p. 198–201° (EtOH). [α]_D²⁶ = +36.6 (*c* = 0.32, CH₂Cl₂). IR (KBr): 3366, 1689 (C=O), 1525, 1429, 1422, 1251, 1169, 1021, 922, 838. ¹H-NMR (CDCl₃): 1.34 (*s*, *t*-BuO); 3.02–3.16 (*m*, H_a–C(2)); 3.27 (*dd*, *J* = 5.7, 13.6, H_b–C(2)); 5.77 (*br. s*, H–C(1), NH); 6.33 (*s*, H–C(4'')); 7.07–7.16 (*m*, 2 H of Ph); 7.17–7.28 (*m*, 3 H of Ph); 7.63 (*d*, *J* = 9.4, H–C(5'')); 7.64 (*s*, H–C(3'')); 8.21 (*br. d*, *J* = 9.4, H–C(4'')). ¹³C-NMR (CDCl₃): 28.3; 40.8; 49.9; 79.7; 110.1; 123.2; 126.7; 128.4; 129.3; 130.6; 137.1; 142.3; 146.5; 154.5; 155.0; 155.8. Anal. calc. for C₂₀H₂₂ClN₅O₂ (399.87): C 60.07, H 5.55, N 17.51; found: C 60.05, H 5.64, N 17.55.

Benzyl {(1*S*)-2-Phenyl-1-[1-(6-phenylpyridazin-3-yl)-1*H*-pyrazol-5-yl]ethyl}carbamate (**21k**). From **4a** (0.190 g, 0.5 mmol), **18i** (0.093 g, 0.5 mmol), and 37% aq. HCl soln. (2 drops, *ca.* 0.6 mmol) by *G.P. A* (reflux for 1.5 h): 0.185 g (78%) of **21k**. M.p. 203–206°. [α]_D²⁴ = +20.7 (*c* = 0.50, CHCl₃). IR (KBr): 3337, 1694 (C=O), 1538, 1427, 1396, 1264, 1051, 924, 802, 745, 688. ¹H-NMR (CDCl₃): 3.24–3.38 (*m*, H_a–C(2)); 5.04 (*s*, PhCH₂O); 5.79–5.89 (*m*, H–C(1)); 6.32 (*d*, *J* = 1.5, H–C(4'')); 6.50 (*br. d*, *J* = 6.4, NH); 7.05–7.13 (*m*, 2 H of Ph); 7.16–7.24 (*m*, 3 H of Ph); 7.27–7.40 (*m*, 5 H of Ph); 7.51–7.61 (*m*, 3 H of Ph); 7.64 (*d*, *J* = 1.5, H–C(3'')); 8.01 (*d*, *J* = 9.0, H–C(5'')); 8.06–8.14 (*m*, 2 H of Ph); 8.28 (*d*, *J* = 9.0, H–C(4'')). ¹H-NMR ((D₆)DMSO): 2.86 (*dd*, *J* = 10.2, 13.2, H_a–C(2)); 3.23 (*dd*, *J* = 3.8, 13.6, H_b–C(2)); 4.92 (*s*, PhCH₂O); 5.97–6.07 (*m*, H–C(1)); 6.65 (*d*, *J* = 1.5, H–C(4'')); 6.86 (*br. s*, NH); 7.16–7.42 (*m*, 9 H of Ph); 7.56–7.66 (*m*, 3 H of Ph); 7.85 (*d*, *J* = 1.5, H–C(3'')); 8.08–8.14 (*m*, 1 H of

Ph); 8.20 (*d*, *J* = 9.2, H–C(5'')); 8.22–8.26 (*m*, 2 H of Ph); 8.45 (*d*, *J* = 9.2, H–C(4'')). ¹³C-NMR ((D₆)DMSO): 41.8; 51.6; 66.1; 108.6; 122.1; 127.2; 127.8; 128.27; 128.35; 128.5; 128.9; 129.1; 130.01; 130.02; 131.1; 136.2; 137.9; 139.2; 142.9; 149.1; 156.3; 156.5; 158.3. EI-MS: 475 (*M*⁺). EI-HR-MS: 476.207780 (C₂₉H₂₆N₅O₂⁺, [*M* + H]⁺; calc. 476.208650). Anal. calc. for C₂₉H₂₅N₅O₂ (475.54): C 73.25, H 5.30, N 14.73; found: C 72.92, H 5.38, N 14.34.

Benzyl [(1*R*,2*R*)-2-Hydroxy-1-(1-phenyl-1*H*-pyrazol-5-yl)propyl]carbamate (23a). From **10** (181 mg, 0.5 mmol) and **18b** (0.072 g, 0.5 mmol) by *G.P. B* (stirring at 80° for 6 h). CC (AcOEt/hexanes 1:1) gave 0.161 g (92%) of **23a**. Oil. [α]_D²⁴ = +37.05 (*c* = 1.88, CHCl₃). IR (NaCl): 3311, 1709 (C=O), 2598, 1503, 1455, 1399, 1272, 1063, 928, 766, 697. ¹H-NMR (CDCl₃): 1.08 (*d*, *J* = 6.4, Me(3)); 1.85 (*s*, OH); 3.76–3.86 (*m*, H–C(2)); 4.77–4.93 (*m*, H–C(1)); 5.09 (*s*, PhCH₂O); 5.44 (*d*, *J* = 6.4, NH); 6.38 (*d*, *J* = 1.9, H–C(4'')); 7.28–7.55 (*m*, 2 Ph); 7.63 (*dd*, *J* = 0.5, 1.9, H–C(3')). ¹³C-NMR (CDCl₃): 20.5; 53.7; 67.5; 69.4; 105.7; 126.5; 128.5; 128.7; 128.97; 129.02; 129.7; 136.6; 139.7; 140.3; 143.4; 156.7. EI-MS: 352 ([*M* + H]⁺). FAB-MS: 352 ([*M* + H]⁺). EI-HR-MS: 352.167200 (C₂₀H₂₂N₃O₃⁺, calc. [*M* + H]⁺; 352.166117).

Benzyl [(1*R*,2*R*)-2-Hydroxy-1-[1-(6-phenylpyridazin-3-yl)-1*H*-pyrazol-5-yl]propyl]carbamate (23b). From **10** (181 mg, 0.5 mmol), **18i** (0.093 g, 0.5 mmol), and 37% aq. HCl soln. (2 drops, *ca.* 0.6 mmol) by *G.P. A* (reflux for 2 h): 0.114 g (63%) of **23b**. M.p. 210–211°. [α]_D²⁵ = +30.0 (*c* = 0.5, CHCl₃). IR (KBr): 3510, 1696 (C=O), 1528, 1464, 1435, 1394, 1269, 1231, 1062, 920, 689. ¹H-NMR (CDCl₃): 1.33 (*d*, *J* = 6.0, Me(3)); 2.54 (*s*, OH); 4.40–4.51 (*m*, H–C(2)); 5.08 (*s*, PhCH₂O); 5.65 (*dd*, *J* = 3.0, 8.7, H–C(1)); 6.31 (*d*, *J* = 8.8, NH); 6.52 (*d*, *J* = 1.6, H–C(4'')); 7.27–7.41 (*m*, Ph); 7.49–7.60 (*m*, 3 H of Ph); 7.72 (*d*, *J* = 1.7, H–C(3')); 7.99 (*d*, *J* = 8.9, H–C(5'')); 8.02–8.08 (*m*, 2 H of Ph); 8.25 (*d*, *J* = 9.5, H–C(4'')). ¹H-NMR ((D₆)DMSO): 1.10 (*d*, *J* = 6.0, Me(3)); 3.94–4.05 (*m*, H–C(2)); 4.79 (*d*, *J* = 5.7, OH); 4.99, 5.04 (2*d*, 1:1, *J* = 12.8, PhCH₂O); 5.82 (*dd*, *J* = 4.1, 9.3, H–C(1)); 6.66 (*d*, *J* = 1.5, H–C(4'')); 7.27–7.39 (*m*, 4 H of Ph); 7.53 (*d*, *J* = 9.8, H–C(5'')); 7.55–7.64 (*m*, 3 H of Ph); 7.81 (*d*, *J* = 1.5, H–C(3')); 8.16–8.25 (*m*, 3 H of Ph); 8.46 (*d*, *J* = 9.4, H–C(4'')). ¹³C-NMR (CDCl₃): 21.1; 54.5; 66.4; 68.6; 109.9; 122.7; 127.7; 128.2; 128.5; 128.6; 129.2; 130.0; 131.1; 136.1; 137.9; 142.7; 146.7; 156.6; 157.0; 158.2. EI-MS: 411 ([*M* – H₂O]⁺). EI-HR-MS: 411.170300 (C₂₄H₂₁N₅O₃⁺, calc. [*M* – H₂O]⁺; 411.169525). Anal. calc. for C₂₄H₂₃N₅O₃ (429.47): C 67.12, H 5.40, N 16.31; found: C 67.00, H 5.51, N 16.15.

6. **Benzyl [(1*R*,2*R*)-1-(3-Cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-hydroxypropyl]carbamate (16).** A mixture of **10** (0.181 g, 0.5 mmol), **11c** (54 mg, 0.5 mmol), EtOH (4 ml), and 37% aq. HCl soln. (3 drops, *ca.* 1 mmol) was heated under reflux for 6 h. After cooling, the precipitate was collected by filtration and washed with EtOH and Et₂O to give the first portion of **16**. The filtrate was evaporated and the residue purified by CC (AcOEt/hexanes 1:1) to give a second portion of **16** which was crystallized from CHCl₃. Combined yield: 0.135 g (77%) of **16**. M.p. 168–174°. [α]_D²⁵ = –35.2 (*c* = 0.5, CHCl₃). IR (KBr): 3402, 2228 (C≡N), 1695 (C=O), 1622, 1551, 1511, 1322, 1261, 1215, 1097, 691. ¹H-NMR (CDCl₃): 1.42 (*d*, *J* = 6.4, Me(3)); 2.37 (*d*, *J* = 2.6, OH); 4.46–4.59 (*m*, H–C(1)); 5.12 (*s*, PhCH₂O); 5.40 (*dd*, *J* = 1.9, 8.7, H–C(2)); 6.07 (*d*, *J* = 8.7, NH); 7.06 (*d*, *J* = 4.1, H–C(6'')); 7.29–7.43 (*m*, Ph); 8.37 (*s*, H–C(2'')); 8.69 (*d*, *J* = 4.1, H–C(5'')). ¹³C-NMR (CDCl₃): 20.9; 56.6; 65.8; 66.8; 82.1; 110.0; 114.2; 128.5; 128.7; 129.2; 137.7; 148.2; 150.9; 151.8; 154.5; 157.2. EI-MS: 352 ([*M* + H]⁺). Anal. calc. for C₁₈H₁₇N₅O₃ (351.36): C 61.53, H 4.88, N 19.93; found: C 61.59, H 4.95, N 19.96.

7. **tert-Butyl [(1*S*)-2-Phenyl-1-(2-phenylpyrimidin-4-yl)ethyl]carbamate (17).** A mixture of **4b** (0.173 g, 0.5 mmol), **12** (0.117 g, 0.75 mmol), K₂CO₃ (0.070 g, 0.5 mmol), and EtOH (4 ml) was heated under reflux for 6 h. The mixture was cooled and evaporated, and the residue purified by CC (AcOEt/hexanes 1:2): 0.050 g (27%) of **17**. M.p. 114–116°. [α]_D²⁴ = –2.57 (*c* = 0.50, CHCl₃). IR (KBr): 3383, 2978, 1690 (C=O), 1568, 1559, 1514, 1389, 1169, 1018, 694. ¹H-NMR (CDCl₃): 1.44 (*s*, *t*-BuO); 3.13 (*dd*, *J* = 7.9, 13.2, H_a–C(2)); 3.28 (*dd*, *J* = 5.3, 13.2, H_b–C(2)); 4.93–5.11 (*m*, H–C(1)); 5.62 (*br. d*, *J* = 6.8, NH); 6.76 (*d*, *J* = 4.9, H–C(5'')); 6.98–7.09 (*m*, 2 H of Ph); 7.13–7.24 (*m*, 3 H of Ph); 7.46–7.56 (*m*, 3 H of Ph); 8.41–8.51 (*m*, 2 H of Ph); 8.60 (*d*, *J* = 4.9, H–C(6'')). ¹³C-NMR (CDCl₃): 28.8; 42.5; 56.9; 80.27; 117.6; 127.1; 128.7; 128.8; 129.0; 129.9; 131.2; 137.2; 137.9; 155.6; 157.6; 164.8; 168.5. EI-MS: 375 (*M*⁺). EI-HR-MS: 375.194777 (C₂₃H₂₅N₃O₂⁺, *M*⁺; calc. 375.194677). Anal. calc. for C₂₃H₂₅N₃O₂ (375.46): C 73.57, H 6.71, N 11.19; found: C 73.82, H 6.98, N 11.05.

8. **Compounds 22a–g and 24a,b: General Procedure.** A mixture of *N*-[(benzyloxy)carbonyl]-protected amine **21a,c–e,g,h,k** or **23a,b** (0.5 mmol) in EtOH, THF, or EtOH/THF (10 ml) and 10% Pd/C

(40 mg) was hydrogenated (1 bar) at r.t. for 24 h. The mixture was filtered through a short pad of *Celite*[®] and washed thoroughly with MeOH. The filtrate was evaporated when necessary, the product was purified by CC. Compounds **22a–g** and **24a,b** were prepared in this manner.

(*IS*)-2-Phenyl-1-(1H-pyrazol-5-yl)ethanamine (**22a**). From a mixture **21a/21'a** (0.161 g, 0.5 mmol) in EtOH, CC (CHCl₃/MeOH 10:1) gave 0.086 g (92%) of **22a**. Oil. [α]_D²⁴ = –9.00 (*c* = 1.54, CHCl₃). IR (NaCl): 3177, 2922, 1602, 1584, 1495, 1454, 1380, 927, 768, 700. ¹H-NMR (CDCl₃): 2.86 (*dd*, *J* = 8.7, 13.6, H_a–C(2)); 3.17 (*dd*, *J* = 4.9, 13.6, H_b–C(2)); 4.00 (*br. s.*, NH₂); 4.35 (*dd*, *J* = 4.9, 8.7, H–C(1)); 6.19 (*d*, *J* = 1.9, H–C(4')); 7.16–7.40 (*m*, Ph, H–N(1')); 7.51 (*d*, *J* = 2.3, H–C(3')). ¹H-NMR ((D₆)DMSO): 2.04 (*br. s.*, NH₂); 2.81 (*dd*, *J* = 7.9, 13.2, H_a–C(2)); 3.00 (*dd*, *J* = 6.0, 13.2, H_b–C(2)); 4.11 (*dd*, *J* = 6.0, 7.9, H–C(1)); 6.11 (*s*, H–C(4')); 7.13–7.28 (*m*, Ph); 7.45 (*br. s.*, H–C(3')); 12.45 (*br. s.*, H–N(1')). ¹³C-NMR (CDCl₃): 45.2; 51.1; 102.6; 127.0; 128.9; 129.8; 133.9; 138.8; 152.2. FAB-MS: 188 ([*M* + H]⁺).

(*IS*)-2-Phenyl-1-(1-phenyl-1H-pyrazol-5-yl)ethanamine (**22b**). From **21c** (0.199 g, 0.5 mmol) in EtOH: 0.108 g (82%) of **22b**. Oil. [α]_D²¹ = –12.1 (*c* = 1.97, CHCl₃). IR (NaCl): 3365, 3062, 3028, 2922, 1599, 1503, 1454, 1398, 1199, 1072, 924, 697. ¹H-NMR (CDCl₃): 1.62 (*br. s.*, NH₂); 2.81 (*dd*, *J* = 8.3, 13.4, H_a–C(2)); 3.01 (*dd*, *J* = 5.7, 13.5, H_b–C(2)); 4.26 (*dd*, *J* = 5.7, 8.1, H–C(1)); 6.45 (*d*, *J* = 1.5, H–C(4')); 6.94–7.03 (*m*, 2 H of Ph); 7.14–7.24 (*m*, 3 H of Ph); 7.28–7.35 (*m*, 2 H of Ph); 7.37–7.48 (*m*, 3 H of Ph); 7.63 (*d*, *J* = 1.5, H–C(3')). ¹H-NMR ((D₆)DMSO): 2.04 (*br. s.*, NH₂); 2.82 (*dd*, *J* = 7.2, 13.2, H_a–C(2)); 2.87 (*dd*, *J* = 6.8, 13.2, H_b–C(2)); 4.05 (*dd*, *J* = 6.8, 7.2, H–C(1)); 6.53 (*d*, *J* = 1.9, H–C(4')); 6.90–6.95 (*m*, 2 H of Ph); 7.09–7.20 (*m*, 3 H of Ph); 7.29–7.34 (*m*, 2 H of Ph); 7.38–7.50 (*m*, 3 H of Ph); 7.57 (*d*, *J* = 1.9, H–C(4')). ¹³C-NMR (CDCl₃): 45.3; 49.7; 104.3; 126.3; 127.1; 128.7; 128.9; 129.5; 129.6; 138.2; 140.1; 140.3. EI-MS: 264 ([*M* + H]⁺). EI-HR-MS: 264.150460 (C₁₇H₁₈N₃⁺, [*M* + H]⁺; calc. 264.150073).

(*IS*)-1-[1-(4-Aminophenyl)-1H-pyrazol-5-yl]-2-phenylethanamine (**22c**). From **21d** (0.221 g, 0.5 mmol) in EtOH, CC (CHCl₃/MeOH 10:1) gave 0.132 g (95%) of **22c**. Oil. [α]_D²⁴ = –14.2 (*c* = 1.38, CHCl₃). IR (NaCl): 3343, 3217, 2923, 1627, 1609, 1522, 1400, 1294, 1172, 1078, 929, 834, 701. ¹H-NMR (CDCl₃): 1.81 (*br. s.*, NH₂–C(1)); 2.78 (*dd*, *J* = 8.3, 13.2, H_a–C(2)); 2.99 (*dd*, *J* = 5.7, 13.6, H_b–C(2)); 3.80 (*br. s.*, ArNH₂); 4.17 (*dd*, *J* = 5.7, 8.3, H–C(1)); 6.37 (*d*, *J* = 1.9, H–C(4')); 6.59–6.68 (*m*, 2 H of C₆H₄); 6.94–7.06 (*m*, 2 H of Ph, 2 H of C₆H₄); 7.14–7.28 (*m*, 3 H of Ph); 7.57 (*d*, *J* = 1.9, H–C(3')). ¹³C-NMR (CDCl₃): 45.1; 49.6; 103.5; 115.4; 127.0; 127.7; 128.9; 129.7; 130.8; 138.4; 139.7; 147.3; 147.8. EI-MS: 278 (*M*⁺). EI-HR-MS: 278.143500 (C₁₇H₁₈N₄⁺, *M*⁺; calc. 278.153147).

(*IS*)-1-[1-(4-Methoxyphenyl)-1H-pyrazol-5-yl]-2-phenylethanamine (**22d**). From **21e** (0.214 g, 0.5 mmol) in EtOH: 0.144 g (98%) of **22d**. Oil. [α]_D²⁴ = –4.18 (*c* = 0.96, CHCl₃). IR (NaCl): 3357, 2930, 2838, 1607, 1518, 1455, 1301, 1251, 1027, 837, 701. ¹H-NMR (CDCl₃): 2.96 (*dd*, *J* = 7.2, 13.2, H_a–C(2)); 3.06 (*dd*, *J* = 6.8, 13.2, H_b–C(2)); 3.51 (*br. s.*, NH₂); 3.83 (*s*, MeO); 4.23 (*t*, *J* = 7.2, H–C(1)); 6.56 (*d*, *J* = 1.9, H–C(4')); 6.86–6.92 (*m*, 2 H of C₆H₄); 6.93–6.99 (*m*, of C₆H₄); 7.04–7.11 (*m*, 2 H of Ph); 7.18–7.24 (*m*, 3 H of Ph); 7.59 (*d*, *J* = 1.9, H–C(3')). ¹³C-NMR (CDCl₃): 44.3; 49.6; 55.9; 104.5; 114.6; 127.3; 127.9; 129.0; 129.7; 132.6; 137.3; 140.1; 145.6; 160.0. EI-MS: 294 ([*M* + H]⁺). EI-HR-MS 294.161030 (C₁₈H₂₀N₃O⁺, [*M* + H]⁺; calc. 294.160637).

(*IS*)-2-Phenyl-1-[1-(pyridin-2-yl)-1H-pyrazol-5-yl]ethanamine (**22e**). From **21g** (0.199 g, 0.5 mmol) in EtOH/THF 4:1, CC (CHCl₃/MeOH 10:1) gave 0.112 g (85%) of **22e**. Oil. [α]_D²¹ = –31.4 (*c* = 2.75, CHCl₃). IR (NaCl): 3362, 3024, 2923, 1591, 1578, 1474, 1435, 1386, 1202, 1081, 922, 787, 699. ¹H-NMR (CDCl₃): 1.91 (*br. s.*, NH₂); 2.91 (*dd*, *J* = 9.0, 13.6, H_a–C(2)); 3.29 (*dd*, *J* = 4.9, 13.6, H_b–C(2)); 5.02 (*dd*, *J* = 4.9, 9.0, H–C(1)); 6.45 (*d*, *J* = 1.5, H–C(4')); 7.14–7.40 (*m*, Ph, H–C(5'')); 7.63 (*d*, *J* = 1.5, H–C(3'')); 7.79–7.86 (*m*, H–C(3'')); 7.88–7.94 (*m*, H–C(4'')); 8.45–8.49 (*m*, H–C(6'')). ¹³C-NMR (CDCl₃): 43.7; 50.2; 106.5; 117.0; 121.9; 126.9; 128.8; 129.7; 139.1; 139.4; 141.1; 147.8; 150.0; 153.9. EI-MS: 264 (*M*⁺). EI-HR-MS: 264.138220 (C₁₆H₁₆N₄⁺, *M*⁺; calc. 264.136159).

(*IS*)-2-Phenyl-1-[1-(pyrimidin-2-yl)-1H-pyrazol-5-yl]ethanamine (**22f**). From **21h** (0.200 g, 0.5 mmol) in EtOH, CC (CHCl₃/MeOH 10:1) gave 0.072 g (69%) of **22f**. Oil. [α]_D²¹ = –55.8 (*c* = 1.25, CHCl₃). IR (NaCl): 3253, 2926, 1587, 1525, 1453, 1420, 799, 700. ¹H-NMR (CDCl₃): 2.01 (*br. s.*, NH₂); 2.92 (*dd*, *J* = 9.0, 13.6, H_a–C(2)); 3.29 (*dd*, *J* = 4.5, 13.6, H_b–C(2)); 5.07 (*dd*, *J* = 4.5, 9.0, H–C(1)); 6.51 (*d*, *J* = 1.5, H–C(4')); 7.18–7.41 (*m*, Ph, H–C(5'')); 7.73 (*d*, *J* = 1.5, H–C(3'')); 8.82 (*d*, *J* = 4.9, H–

C(4''), H–C(6'')). ¹³C-NMR (CDCl₃): 43.7; 50.4; 107.6; 119.0; 127.0; 128.9; 129.7; 139.0; 142.5; 151.2; 158.4; 159.1. EI-MS: 265 (*M*⁺), 264 ([*M*–H]⁺). EI-HR-MS: 265.133070 (C₁₅H₁₅N₅⁺, *M*⁺; calc. 265.132746).

(1*S*)-2-Phenyl-1-[1-(6-phenylpyridazin-3-yl)-1*H*-pyrazol-5-yl]ethanamine (**22g**). From **21k** (0.238 g, 0.5 mmol) in THF. CC (CHCl₃/MeOH 20:1) and then MPLC (CHCl₃/MeOH 30:1) gave 0.120 g (70%) of **22g**. Oil. [α]_D²⁴ = –36.9 (*c* = 1.78, CHCl₃). IR (NaCl): 3360, 3061, 2924, 1535, 1464, 1453, 1431, 1396, 921, 747, 697. ¹H-NMR (CDCl₃): 2.12 (br. s, NH₂); 3.03 (*dd*, *J* = 8.7, 13.3, H_a–C(2)); 3.31 (*dd*, *J* = 5.2, 13.3, H_b–C(2)); 5.26 (*dd*, *J* = 5.2, 8.7, H–C(1)); 6.57 (*d*, *J* = 1.8, H–C(4'')); 7.15–7.30 (*m*, Ph); 7.49–7.59 (*m*, 3 H of Ph); 7.72 (*d*, *J* = 1.8, H–C(3'')); 7.98 (*d*, *J* = 9.2, H–C(5'')); 8.05–8.13 (*m*, 2 H of Ph); 8.18 (*d*, *J* = 9.2, H–C(4'')). ¹³C-NMR (CDCl₃): 43.9; 50.3; 107.8; 121.8; 126.95; 126.96; 127.4; 128.8; 129.5; 129.9; 130.6; 136.1; 138.8; 142.4; 150.2; 156.1; 158.4. EI-MS: 341 (*M*⁺). EI-HR-MS: 341.165120 (C₂₁H₁₉N₅⁺, *M*⁺; calc. 341.164046).

(1*R*,2*R*)-1-Amino-1-(1-phenyl-1*H*-pyrazol-5-yl)propan-2-ol (**24a**). From **23a** in EtOH. CC (CHCl₃/MeOH 10:1) gave 0.090 g (83%) of **24a**. Oil. [α]_D²⁶ = +9.0 (*c* = 0.5, CHCl₃). IR (NaCl): 3356, 1595, 1530, 1501, 1455, 1398, 1201, 1115, 1067, 1007, 928, 768. ¹H-NMR (CDCl₃): 0.99 (*d*, *J* = 6.0, Me(3)); 2.48 (*s*, OH, NH₂); 3.66 (*d*, *J* = 7.9, H–C(1)); 3.75 (*dq*, *J* = 6.0, 7.9, H–C(2)); 6.32 (*d*, *J* = 1.9, H–C(4'')); 7.39–7.52 (*m*, Ph); 7.61 (*dd*, *J* = 0.5, 1.9, H–C(3'')). ¹³C-NMR (CDCl₃): 20.1; 54.0; 71.0; 104.0; 126.5; 129.0; 129.7; 139.8; 140.6; 146.1. EI-MS: 218 ([*M*–H]⁺). FAB-MS: 218 ([*M*–H]⁺). EI-HR-MS: 218.129900 (C₁₂H₁₆N₃O⁺, [*M*–H]⁺; calc. 218.129337).

(1*R*,2*R*)-1-Amino-1-[1-(6-phenylpyridazin-3-yl)-1*H*-pyrazol-3-yl]propan-2-ol (**24b**). From **23b** in EtOH/THF 3:7. CC (CHCl₃/MeOH 8:1) gave 0.094 g (64%) of **24b**. M.p. 113–118°. [α]_D²⁶ = +2.0 (*c* = 0.5, CHCl₃). IR (KBr): 3447, 1634, 1585, 1561, 1533, 1461, 1432, 1393, 1202, 1026, 937, 781, 743, 687. ¹H-NMR (CDCl₃): 1.21 (*d*, *J* = 6.0, Me(3)); 2.41 (br. s, OH, NH₂); 4.06 (*dq*, *J* = 6.1, 7.7, H–C(2)); 4.55 (*d*, *J* = 7.7, H–C(1)); 6.47 (*d*, *J* = 1.7, H–C(4'')); 7.49–7.61 (*m*, 3 H of Ph); 7.74 (*d*, *J* = 1.7, H–C(3'')); 8.03 (*d*, *J* = 9.2, H–C(5'')); 8.06–8.11 (*m*, 2 H of Ph); 8.26 (*d*, *J* = 9.2, H–C(4'')). ¹³C-NMR (CDCl₃): 20.4; 54.6; 69.3; 107.7; 122.1; 127.2; 127.4; 129.6; 130.7; 135.9; 142.6; 148.2; 156.0; 158.6. EI-MS: 296 ([*M*–H]⁺). FAB-MS: 296 ([*M*–H]⁺). EI-HR-MS: 296.152001 (C₁₆H₁₈N₅O⁺, [*M*–H]⁺; calc. 296.151135).

9. *X-Ray Crystal-Structure Determination of 15b*. A prismatic colorless crystal with dimensions 0.80×0.35×0.20 mm was used for data collection at r.t. on a *Nonius-Kappa-CCD* diffractometer with graphite monochromated MoK_α radiation in the ω scan mode. The θ range was 2.55–26.02°. The data were processed with the DENZO [20] program. The number of integrated, symmetry-independent, and observed ($F^2 > 2.0\sigma F^2$) reflections were 26511, 2181, and 1589, respectively. The structure was solved by direct methods with SIR97 [21]. We employed full-matrix least-squares refinements on *F* magnitudes with anisotropic displacement factors for all non-H-atoms. The positions of H-atoms bonded to C(1), C(2), and N(4) were obtained from the difference *Fourier* map while the remaining were calculated. The parameters of H-atoms were not refined. In the final cycle of the refinement, we used 1949 reflections (included were those less-than reflections for which *F_C* was greater than *F_O*) and 226 parameters. The final *R*, *R_w*, and *S* were 0.061, 0.034, and 1.479, resp. The residual density in final difference map was max. 0.203 and min. –0.300 e/Å³. The Xtal3.6 [22] system of crystallographic programs was used for the structure refinement and interpretation. ORTEPII [23] was used to produce molecular graphics.

CCDC-268823 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the *Cambridge Crystallographic Data Centre* via www.ccdc.cam.ac.uk/data_request/cif.

REFERENCES

- [1] J. Mulzer, 'Basic Principles of EPC Synthesis' in 'Stereoselective Synthesis, Methods of Organic Chemistry', Ed. G. Helmchen, Houben-Weyl, 4th edn., 1996, Vol. 1, p. 75–146.
- [2] L. Pu, H.-B. Yu, *Chem. Rev.* **2001**, *101*, 757; K. Soai, S. Niwa, *Chem. Rev.* **1992**, *92*, 833; M. Kitamura, S. Suga, K. Kawai, R. Noyori, *J. Am. Chem. Soc.* **1986**, *108*, 6071.
- [3] T. Mehler, J. Martens, *Tetrahedron: Asymmetry* **1993** *4*, 1983; J. Martens, Ch. Dauelsberg, W. Behnen, S. Wallbaum, *Tetrahedron: Asymmetry* **1992**, *3*, 347.

- [4] a) B. Stanovnik, J. Svete, *Mini-Rev. Org. Chem.* **2005**, 2, 211; b) J. Svete, *J. Heterocycl. Chem.* **2005**, 42, 361; c) B. Stanovnik, J. Svete, *Chem. Rev.* **2004**, 104, 2433; d) J. Svete, *Monatsh. Chem.* **2004**, 135, 629; e) J. Svete, *J. Heterocycl. Chem.* **2002**, 39, 437; f) B. Stanovnik, J. Svete, *Synlett* **2000**, 1077; g) B. Stanovnik, J. Svete, *Targets Heterocycl. Systems* **2000**, 4, 105; h) B. Stanovnik, *J. Heterocycl. Chem.* **1999**, 36, 1581.
- [5] U. Grošelj, D. Bevk, R. Jakše, A. Meden, S. Pirc, S. Rečnik, B. Stanovnik, J. Svete, *Tetrahedron: Asymmetry* **2004**, 15, 2367; U. Grošelj, D. Bevk, R. Jakše, S. Rečnik, A. Meden, B. Stanovnik, J. Svete, *Tetrahedron* **2005**, 61, 3991; L. Pezdirc, V. Jovanovski, D. Bevk, R. Jakše, S. Pirc, A. Meden, B. Stanovnik, J. Svete, *Tetrahedron* **2005**, 61, 3977; U. Grošelj, D. Bevk, R. Jakše, A. Meden, S. Rečnik, B. Stanovnik, J. Svete, *Synthesis* **2005**, 1087; U. Grošelj, D. Bevk, R. Jakše, A. Meden, B. Stanovnik, J. Svete, *Tetrahedron: Asymmetry* **2005**, 16, 2187.
- [6] S. Pirc, D. Bevk, S. Golič Grdadolnik, J. Svete, *ARKIVOC* **2003**, xiv, 37; J. Westman, R. Lundin, *Synthesis* **2003**, 1025; P. Čebašek, J. Wagger, D. Bevk, R. Jakše, J. Svete, B. Stanovnik, *J. Comb. Chem.* **2004**, 6, 356.
- [7] L. Selič, R. Jakše, K. Lampič, L. Golič, S. Golič Grdadolnik, B. Stanovnik, *Helv. Chim. Acta* **2000**, 83, 2802; R. Jakše, S. Rečnik, J. Svete, A. Golobič, L. Golič, B. Stanovnik, *Tetrahedron* **2001**, 57, 8395; U. Grošelj, A. Drobnič, S. Rečnik, J. Svete, B. Stanovnik, A. Golobič, N. Lah, I. Leban, A. Meden, S. Golič Grdadolnik, *Helv. Chim. Acta* **2001**, 84, 3403; R. Jakše, V. Krošelj, S. Rečnik, G. Soršak, J. Svete, B. Stanovnik, S. Golič Grdadolnik, *Z. Naturforsch., B* **2002**, 57, 453.
- [8] R. Jakše, J. Svete, B. Stanovnik, A. Golobič, *Tetrahedron* **2004**, 60, 4601; Z. Časar, D. Bevk, J. Svete, B. Stanovnik, *Tetrahedron* **2005**, 61, 7508.
- [9] L. De Luca, M. Falorini, G. Giacomelli, A. Porcheddu, *Tetrahedron Lett.* **1999**, 40, 8701.
- [10] L. De Luca, G. Giacomelli, A. Porcheddu, A. M. Spannedda, M. Falorini, *Synthesis* **2000**, 1295.
- [11] W. S. Saari, T. E. Fisher, *Synthesis* **1990**, 453.
- [12] D. A. Evans, E. Hu, J. S. Tedrow, *Org. Lett.* **2001**, 3, 3133.
- [13] A. Hanzlowsky, B. Jelenčič, S. Rečnik, J. Svete, A. Golobič, A. B. Stanovnik, *J. Heterocycl. Chem.* **2003**, 40, 487.
- [14] H. Dube, N. Gommermann, P. Knochel, *Synthesis* **2004**, 2015.
- [15] O. Červinka, P. Malon, *Coll. Czech. Chem. Commun.* **1977**, 42, 3464.
- [16] F. J. L. Herrera, M. S. P. Gonzáles, R. P. Aguas, *J. Chem. Soc., Perkin Trans. 1* **1989**, 2401.
- [17] K. Shinkawa, S. Ban, M. Yoneda, *J. Pharm. Soc. Jpn.* **1953**, 73, 598.
- [18] J. Druy, K. Meier, K. Eichenberger, *Helv. Chim. Acta* **1954**, 37, 121.
- [19] D. Libermann, A. Rouaix, *Bull. Soc. Chim. Fr.* **1959**, 1793.
- [20] Z. Otwinowski, W. Minor, *Methods Enzymol.* **1997**, 276, 307.
- [21] A. Altomare, M. C. Burla, M. Camalli, G. Cascarano, C. Giacovazzo, A. Guagliardi, A. Moliterni, G. Polidori, R. Spagna, *J. Appl. Crystallogr.* **1999**, 32, 115.
- [22] 'Xtal3.6 System' Eds. S. R. Hall, D. J. du Boulay, and R. Olthof-Hazekamp, University of Western Australia, 1999.
- [23] C. K. Johnson, 'ORTEPII', Report ORNL-5138, Oak Ridge National Laboratory, Oak Ridge, Tennessee, USA, 1976.

Received August 26, 2005